Back to the main directory
Company Analysis / Equity
- Pfizer Hints At Progress On Remoxy, Posidur Under Review by Zacks
- Sum-Of-Parts Shows Durect Is Vastly Undervalued - Initiating Coverage by Zacks
- EVAR: $15M Investment, Additional Positive Outcomes Data by Zacks
- EVAR: Altura Acquisition, Not Cheap But Makes Sense by Zacks
- EVAR: Benefits from IntelliFlex, Sales Reorg Not Fully Realized by Zacks
- EVAR: Exploiting High Neck Angle Stent- Graft Market. Initiating Coverage at Outperform by Zacks
- EVAR: Q3: Japan Going Strong, Hiccups In All Other Territories. Altura Should Make Contribution in 2016 by Zacks
- EVAR: Very Solid Q2: 107% Revenue Growth, Big Gross Margin, OpEx Falls by Zacks
- EYEG: Clinical Timelines On-Track. EGP- 437 Data in 2H 2016. Jade s Candidate to Initiate Clinicals This year by Zacks
- EYEG: Positive Cataract Surgery Data, De Novo 510(k) Pathway Confirmed for CMHAS by Zacks
- EYEG: Positive Post-Cataract Surgery Interim Results. Pivotal Study Could Initiate By Year-End by Zacks
- FNJN: 10Q Hints at New Deals Coming Soon by Zacks
- FNJN: Additional Blue Coat Lawsuit Filed, Just as First Trial is Scheduled to Start on Monday by Zacks
- FNJN: First International License, First Cross-license and No Litigation Needed by Zacks
- FNJN: Raising Q4 and Full Year Estimates Due to Avast License by Zacks
- FNJN: Will Blue Coat s Acquisition Prompt a Licensing Deal? by Zacks
- FNJN: Zacks Company Report Earnings Update $8 Million Websense License Revealed by Zacks
- FNJN: Zacks Company Report Finjan Wins $15 m from Sophos by Zacks
- FNJN: Zacks Company Report Proofpoint Settled, Raising Estimates by Zacks
- 2Q:16 Financial and Operation Results; LPCN in Process of Resolving CRL. by Zacks
- Axxent Revenue Ramping Despite Reimbursement Issue by Zacks
- FDA Post Action Meeting Provides Clarity on Tlando Timeline. by Zacks
- GNMX: Name Change To Aevi Genomic Medicine, Inc by Zacks
- ICAD: Big Q3. Upward Revision to Guidance. DermEbx Looks Like A Winner by Zacks
- ICAD: DermEbx / Radion Acquisition Looks Like a Real Win by Zacks